CDC logo Tuberculosis Information CD-ROM   Image of people
   
1
spacer image

Table 2. Regimen Options for Treatment of Latent TB Infection for Persons with HIV Infection, 2000

Updated August 2003
Drug Regimen Comments
Daily Twice Weekly
Children/
Duration
Adults/
Duration
Children/
Duration
Adults/
Duration
INH

9 months


9 months


9 months


9 months

Minimum of 270 doses administered within 12 months

Twice-weekly regimens should consist of at least 76 doses administered within 12 months.

Directly observed treatment (DOT) of LTBI should be used when twice-weekly dosing is used.

INH can be administered concurrently with NRTIs, PIs, or NNRTIs

Contraindicated for persons who have active hepatitis and end-stage liver disease

RIF 4 months 4 months Not recommended Minimum of 120 doses administered within 6 months

For persons who are contacts of patients with INH-resistant, RIF-susceptible TB

Acceptable alternative; may be used for patients who cannot tolerate INH

Most PIs or delavirdine should not be administered concurrently with RI; Rifabutin with appropriate dose adjustments, can be used with PIs (saquinavir should be augmented with ritonavir) and NNRTIs (except delavirdine).

RIF and PZA Should generally not be offered

A TB/LTBI expert should be consulted prior to the use of this regimen.

RFB and PZA Should generally not be offered

Footnotes

INH - isoniazid; PZA - pyrazinamide; RFB - rifabutin; RIF- rifampin; DOPT- directly observed preventive therapy; PIs - protease inhibitors; NNRTIs - nonnucleoside reverse transcriptase inhibitors; NRTIs - nucleoside reverse transcriptase inhibitors; HIV - human immunodeficiency virus; LTBI - latent TB infection

Note: For patients whose organisms are resistant to 1 or more drugs, administer at least 2 drugs to which there is demonstrated susceptibility and consult a TB medical expert. Clinicians should review the drug-susceptibility pattern of the M. tuberculosis strain isolated from the infecting source-patient before choosing a preventive therapy regimen.

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333